ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers)...
- Mechanism
- Curator reviewed
ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, should lower blood glucose and help control type 2 diabetes.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- ISIS 325568
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ISIS 325568, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account